The release of the snapshot containing the respective simulations can be found here:
https://github.com/Open-Systems-Pharmacology/Rifampicin-Midazolam-DDI/releases/tag/v1.2

The  rifampicin / midazolam interaction was evaluated using 24 clinical DDI studies including 43 different clinical settings ([Backman 1996](#4-references), [Backman 1998](#4-references), [Björkhem-Bergman 2013](#4-references), [Chattopadhyay 2018](#4-references),[Chung 2006](#4-references), [Eap 2004](#4-references), [Gorski 2003](#4-references), [Gurley 2006](#4-references), [Gurley 2008a](#4-references), [Kharasch 1997](#4-references), [Kharasch 2004](#4-references), [Kharasch 2011](#4-references), [Kim 2018](#4-references), [Link 2008](#4-references), [Lutz 2018](#4-references), [Phimmasone 2001](#4-references), [Prueksaritanont 2017](#4-references), [Reitman 2011](#4-references), [Shin 2013](#4-references), [Shin 2016](#4-references), [Szalat 2007](#4-references), [van Dyk 2018](#4-references), [Wiesinger 2011](#4-references), [Yu 2004](#4-references)).

In the study by [Eap 2004](#4-references), the induction of CYP3A4 by rifampicin was evaluated using first 0.075 mg and one day later 7.5 and orally administered midazolam. The magnitude of the DDI with the low dose was much lower than for the higher dose (AUC ratio 0.44 vs. 0.09), which can actually only be explained by issues with the limit of detection after induction for the small midazolam dose considering the entire set of observed data. Therefore, as well as in [Almond 2016](#4-references), the dataset of the low dose setting was excluded from this analysis.



| DataID | Enzyme | Perpetrator / victim   | Study design                                                 | Comment                                                      | Clinical study                       |
| ------ | ------ | ---------------------- | ------------------------------------------------------------ | ------------------------------------------------------------ | ------------------------------------ |
| 54     | CYP3A4 | Rifampicin / midazolam | Rifampicin: **600** mg po once daily (5 doses)<br />Midazolam: 15 mg **PO** single dose, **17** h after **5<sup>th</sup>** rifampicin dose |                                                              | [Backman 1996](#4-references)         |
| 56     | CYP3A4 | Rifampicin / midazolam | Rifampicin: **600** mg po once daily (5 doses)<br />Midazolam: 15 mg **PO** single dose, **17** h after **5<sup>th</sup>** rifampicin dose (Phase IV) |                                                              | [Backman 1998](#4-references)         |
| 57     | CYP3A4 | Rifampicin / midazolam | Rifampicin: **600** mg po once daily (5 doses)<br />Midazolam: 15 mg **PO** single dose, **7 days** after **5<sup>th</sup>** rifampicin dose (Phase V) |                                                              | [Backman 1998](#4-references)         |
| 1355 | CYP3A4 | Rifampicin / midazolam | Rifampicin: **10** mg po once daily (14 doses)<br />Midazolam: 4 mg **PO** single dose, **1 day** after **14<sup>th</sup>** rifampicin dose | | [Björkhem-Bergman 2013](#4-references) |
| 1356 | CYP3A4 | Rifampicin / midazolam | Rifampicin: **20** mg po once daily (14 doses)<br />Midazolam: 4 mg **PO** single dose, **1 day** after **14<sup>th</sup>** rifampicin dose | | [Björkhem-Bergman 2013](#4-references) |
| 1357 | CYP3A4 | Rifampicin / midazolam | Rifampicin: **100** mg po once daily (14 doses)<br />Midazolam: 4 mg **PO** single dose, **1 day** after **14<sup>th</sup>** rifampicin dose | | [Björkhem-Bergman 2013](#4-references) |
| 1362 | CYP3A4 | Rifampicin / midazolam | Rifampicin: **600** mg po once daily morning administrations (11 doses), 8<sup>th</sup> dose of rifampicin was taken in the evening (12 h after intake of midazolam)<br />Midazolam: 1 mg **PO** single dose on **day 8** (24 hours after the **7<sup>th</sup>** rifampicin dose) | Subjects received a single dose of vilaprisan 4 mg simultaneously with midazolam (in both phases). | [Chattopadhyay 2018](#4-references) |
| 113    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **600** mg po once daily (9 doses)<br />Midazolam: 0.075 mg/kg **PO** single dose, **22** h after **7<sup>th</sup>** rifampicin dose |                                                              | [Chung 2006](#4-references)           |
| 129    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **450** mg po once daily (5 doses)<br />Midazolam: 0.075 mg **PO** single dose, **18** h after **4<sup>th</sup>** rifampicin dose | Dataset excluded (see comment above) | [Eap 2004](#4-references)             |
| 132    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **450** mg po once daily (5 doses)<br />Midazolam: 7.5 mg **PO** single dose, **18** h after **5<sup>th</sup>** rifampicin dose |                                                              | [Eap 2004](#4-references)             |
| 179    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **600** mg po once daily (7 doses)<br />Midazolam: 0.05 mg/kg **IV** single dose, **12** h after **6<sup>th</sup>** rifampicin dose |                                                              | [Gorski 2003](#4-references)          |
| 177    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **600** mg po once daily (7 doses)<br />Midazolam: 6 mg **PO** single dose, **12** h after **6<sup>th</sup>** rifampicin dose | Subjects received a 4 mg midazolam dose in control phase.    | [Gorski 2003](#4-references)          |
| 215    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **300** mg po twice daily (14 doses, 7 days)<br />Midazolam: 8 mg **PO** single dose, **2** h after **13<sup>th</sup>** rifampicin dose |                                                              | [Gurley 2006](#4-references)          |
| 221    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **300** mg po twice daily (14 doses, 7 days)<br />Midazolam: 8 mg **PO** single dose, **2** h after **13<sup>th</sup>** rifampicin dose |                                                              | [Gurley 2008a](#4-references)         |
| 276    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **600** mg po once daily (5 doses)<br />Midazolam: 1 mg **IV** single dose, **24** h after **5<sup>th</sup>** rifampicin dose |                                                              | [Kharasch 1997](#4-references)        |
| 280    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **600** mg po once daily (6 doses)<br />Midazolam: 1 mg **IV** single dose, **8** h after **5<sup>th</sup>** rifampicin dose |                                                              | [Kharasch 2004](#4-references)        |
| 286    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **600** mg po once daily (6 doses)<br />Midazolam: 3 mg **PO** single dose, **8** h after **6<sup>th</sup>** rifampicin dose |                                                              | [Kharasch 2004](#4-references)        |
| 294    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **5** mg po once daily (6 doses)<br />Midazolam: 1 mg **IV** single dose, **12** h after **5<sup>th</sup>** rifampicin dose |                                                              | [Kharasch 2011](#4-references)        |
| 295    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **10** mg po once daily (6 doses)<br />Midazolam: 1 mg **IV** single dose, **12** h after **5<sup>th</sup>** rifampicin dose |                                                              | [Kharasch 2011](#4-references)        |
| 296    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **25** mg po once daily (6 doses)<br />Midazolam: 1 mg **IV** single dose, **12** h after **5<sup>th</sup>** rifampicin dose |                                                              | [Kharasch 2011](#4-references)        |
| 297    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **75** mg po once daily (6 doses)<br />Midazolam: 1 mg **IV** single dose, **12** h after **5<sup>th</sup>** rifampicin dose |                                                              | [Kharasch 2011](#4-references)        |
| 304    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **5** mg po once daily (6 doses)<br />Midazolam: 3 mg **PO** single dose, **12** h after **6<sup>th</sup>** rifampicin dose |                                                              | [Kharasch 2011](#4-references)        |
| 305    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **10** mg po once daily (6 doses)<br />Midazolam: 3 mg **PO** single dose, **12** h after **6<sup>th</sup>** rifampicin dose |                                                              | [Kharasch 2011](#4-references)        |
| 306    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **25** mg po once daily (6 doses)<br />Midazolam: 3 mg **PO** single dose, **12** h after **6<sup>th</sup>** rifampicin dose |                                                              | [Kharasch 2011](#4-references)        |
| 307    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **75** mg po once daily (6 doses)<br />Midazolam: 3 mg **PO** single dose, **12** h after **6<sup>th</sup>** rifampicin dose |                                                              | [Kharasch 2011](#4-references)        |
| 2036   | CYP3A4 | Rifampicin / midazolam | Rifampicin: **600** mg po once daily (10 doses)<br  />Midazolam: 2.5 mg **IV** single dose, **simultaneous** with **10<sup>th</sup>**  rifampicin dose | Only assessment in male subjects simulated.<br />Subjects received a 1 mg midazolam dose in control phase. Observed reported dose-normalized AUCR back-calculated to non dose-normalized AUCR. | [Kim 2018](#4-references)             |
| 342    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **600** mg po once daily (6 doses)<br />Midazolam: 2 mg **IV** single dose, **24** h after **6<sup>th</sup>** rifampicin dose |                                                              | [Link 2008](#4-references)            |
| 344    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **600** mg po once daily (6 doses)<br />Midazolam: 7.5 mg  **PO** single dose, **24** h after **6<sup>th</sup>** rifampicin dose |                                                              | [Link 2008](#4-references)            |
| 1350 | CYP3A4 | Rifampicin / midazolam | Rifampicin: **2** mg po once daily (18 doses)<br />Midazolam: 2 mg  **PO** single dose, **12** h after **10<sup>th</sup>** rifampicin dose | Cohort2, <br />Cocktail study | [Lutz 2008](#4-references) |
| 1351 | CYP3A4 | Rifampicin / midazolam | Rifampicin: **10** mg po once daily (18 doses)<br />Midazolam: 2 mg  **PO** single dose, **12** h after **10<sup>th</sup>** rifampicin dose | Cohort 1,<br />Cocktail study | [Lutz 2008](#4-references) |
| 1352 | CYP3A4 | Rifampicin / midazolam | Rifampicin: **10** mg po once daily (18 doses), then **75** mg po once daily (18 doses) <br />Midazolam: 2 mg  **PO** single dose, **12** h after **10<sup>th</sup>** 75 mg rifampicin dose | Cohort 1,<br />Cocktail study | [Lutz 2008](#4-references) |
| 1353 | CYP3A4 | Rifampicin / midazolam | Rifampicin: **2** mg po once daily (18 doses), then **600** mg po once daily (18 doses) <br />Midazolam: 2 mg  **PO** single dose, **12** h after **10<sup>th</sup>** 600mg rifampicin dose | Cohort 2,<br />Cocktail study | [Lutz 2008](#4-references) |
| 389    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **600** mg po once daily (5 doses)<br />Midazolam: 1 mg **IV** single dose, **10** h after **5<sup>th</sup>** rifampicin dose |                                                              | [Phimmasone 2001](#4-references)      |
| 1098   | CYP3A4 | Rifampicin / midazolam | Rifampicin: **600** mg po SD<br />Midazolam: 10 µg  **PO** single dose, **simultaneous** with rifampicin dose |                                                              | [Prueksaritanont 2017](#4-references) |
| 392    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **600** mg po once daily (4 weeks)<br />Midazolam: 2 mg **PO**  single dose, **simultaneous** with **28<sup>th</sup>** rifampicin dose | PK data of midazolam administered 28 days after the last rifampicin dose served as *control* (reference) | [Reitman 2011](#4-references)         |
| 393    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **600** mg po once daily (4 weeks)<br />Midazolam: 2 mg **PO** single dose, **7 days** after **28<sup>th</sup>** rifampicin dose | PK data of midazolam administered 28 days after the last rifampicin dose served as *control* (reference) | [Reitman 2011](#4-references)         |
| 394    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **600** mg po once daily (4 weeks)<br />Midazolam: 2 mg **PO** single dose, **14 days** after **28<sup>th</sup>** rifampicin dose | PK data of midazolam administered 28 days after the last rifampicin dose served as *control* (reference) | [Reitman 2011](#4-references)         |
| 1092   | CYP3A4 | Rifampicin / midazolam | Rifampicin: **600** mg po once daily (10 doses)<br  />Midazolam: 2.5 mg **IV** single dose, **simultaneous** h with **10<sup>th</sup>**  rifampicin dose | Subjects received a 1 mg midazolam dose in control phase. Observed reported dose-normalized AUCR back-calculated to non dose-normalized AUCR. | [Shin 2013](#4-references)            |
| 1095   | CYP3A4 | Rifampicin / midazolam | Rifampicin: **600** mg po once daily (10 doses)<br  />Midazolam: 2.5 mg **IV** single dose, **simultaneous** h with **10<sup>th</sup>**  rifampicin dose | Subjects received a 1 mg midazolam dose in control phase. Observed reported dose-normalized AUCR back-calculated to non dose-normalized AUCR. | [Shin 2016](#4-references)            |
| 422    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **600** mg po once daily (7 doses)<br />Midazolam: 0.05 mg/kg **IV** single dose, **12** h after **12<sup>th</sup>** rifampicin dose |                                                              | [Szalat 2007](#4-references)          |
| 2002   | CYP3A4 | Rifampicin / midazolam | Rifampicin: **300** mg po once daily (7 doses)<br />Midazolam: 1 mg **PO** single dose, **12** h after **7<sup>th</sup>** rifampicin dose | Only assessment in Caucasian subjects simulated.<br />AUC<sub>0-6h</sub> ratio reported and simulated for comparison. | [van Dyk 2018](#4-references)         |
| 204 | CYP3A4 | Rifampicin / midazolam | Rifampicin: **10** mg po once daily (11 doses)<br />Midazolam: 1 mg **PO** single dose, **12** h after **8<sup>th</sup>** rifampicin dose | In the study midazolam was coadministered with either etonogestrel, dienogest, drospirenone, levonorgestrel or norethindrone. | [Wiesinger 2020](#4-references) |
| 205 | CYP3A4 | Rifampicin / midazolam | Rifampicin: 11 doses of **10** mg po once daily, followed by 11 doses of **600** mg po once daily<br />Midazolam: 1 mg **PO** single dose, **12** h after **8<sup>th</sup>** 600 mg rifampicin dose (after the 19<sup>th</sup> overall rifampicin dose) | In the study midazolam was coadministered with either etonogestrel, dienogest, drospirenone, levonorgestrel or norethindrone. | [Wiesinger 2020](#4-references) |
| 202    | CYP3A4 | Rifampicin / midazolam | Rifampicin: **600** mg po once daily (10 doses)<br />Midazolam: 2 mg **IV** single dose, **24** h after **10<sup>th</sup>** rifampicin dose | Only assessment in CYP3A5\*3/\*3 genotype subjects simulated.<br />Subjects received a 1 mg midazolam dose in control phase. Observed reported dose-normalized AUCR back-calculated to non dose-normalized AUCR. | [Yu 2004](#4-references)              |